WeedMD Inc (CVE:WMD) (OTCQX:WDDMF) said Wednesday it had struck a deal with US-based cannabis wellness house MM Technology Holdings LLC to bring a premium line of products to Canada.
The medical cannabis producer will become the sole Canadian distributor of Mary’s Brands, which manufactures topicals, transdermal patches and gel pens under the Mary’s Medicinals line of products.
WeedMD will manufacture Mary’s Medicinals in house with its own input biomass at its CX Industries facility in Ontario. The Toronto-based company will also market and sell Mary’s Medicinal products using its own distribution channels.
READ: WeedMD appoints prominent Canadian entrepreneur and venture capitalist Bruce Croxon to board of directors
The deal helps WeedMD to expand its cannabis offerings to address an “underserved” wellness and medical market segment, according to the company.
“As we move into the next level of product development, it’s imperative that we strategically partner with established brands that share our core values and Mary's Brands offers a superior product line that is backed by a team truly dedicated to ensuring the quality, integrity and efficacy of its product offerings,” said Angelo Tsebelis, CEO of WeedMD in a statement.
“We’re proud to be selected as Mary’s exclusive Canadian producer and distributor. With our cultivation platform and CX extraction operations fully ramped-up, there's the added pride of developing these renowned products in-house as we expand with new cannabis formats into a lucrative, yet underserved consumer segment.”
Mary’s Brands CEO Jacques Panis told investors that the Colorado-based company was “thrilled” to partner with WeedMD to expand its brand into Canada.
“Our continued desire to innovate on additional product offerings makes this partnership fitting as we look to collaborate with a strong, experienced team that brings unparalleled expertise in cultivation and extraction along with a proven ability to capture unique, next-level distribution channels,” Panis said.
WeedMD will start manufacturing Mary’s Medicinals in the fourth quarter to sell across its medical and adult-use channels.
Contact Angela at angela@proactiveinvestors.com
Follow her on Twitter @AHarmantas